MyFinsight
Home
Blog
About
Proceeds from the revenue
share agreement (as...
$97,750K
Proceeds from exercise of
options and employee...
$14,059K
(680.19%↑ Y/Y)
Net cash provided by
financing activities
$107,017K
(5838.79%↑ Y/Y)
Canceled cashflow
$728K
Decrease in cash, cash
equivalents and restricted...
-$346,226K
(-1867.53%↓ Y/Y)
Canceled cashflow
$107,017K
Maturities and sales of
marketable securities
$170,883K
(-29.32%↓ Y/Y)
(purchase) sale of property
and equipment
-$6K
Equity-based compensation
expense
$16,663K
(-25.84%↓ Y/Y)
Accrued expenses
$4,117K
(271.04%↑ Y/Y)
Accounts payable
$1,843K
(-60.00%↓ Y/Y)
Non-cash interest
expense
$1,580K
Non-cash lease expense
$999K
(-43.81%↓ Y/Y)
Depreciation expense
$409K
(-32.51%↓ Y/Y)
Loss on disposal of
property and equipment
-$43K
Proceeds from issuance of
common stock, net of...
-$728K
Net cash (used in)
provided by investing...
-$381,863K
(-519.14%↓ Y/Y)
Canceled cashflow
$170,889K
Net cash used in
operating activities
-$71,380K
(35.41%↑ Y/Y)
Canceled cashflow
$25,654K
Purchases of marketable
securities
$552,752K
(279.69%↑ Y/Y)
Net loss
-$85,854K
(29.30%↑ Y/Y)
Prepaid expenses and
other current assets
$6,134K
(273.57%↑ Y/Y)
Other non-current
assets
$2,091K
(-74.99%↓ Y/Y)
Amortization of discounts on
marketable securities
$1,741K
(-57.94%↓ Y/Y)
Operating lease liability
-$1,214K
(38.84%↑ Y/Y)
Back
Back
Cash Flow
Apogee Therapeutics, Inc. (APGE)
Apogee Therapeutics, Inc. (APGE)
source: myfinsight.com